Endometrial Cancer, GSK and Jemperli

Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer
Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or recurrent endometrial cancer.
GSK’s Jemperli combination approved by EC for expanded endometrial cancer use
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU to treat certain adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer.
GSK gets expanded EU approval for Jemperli in endometrial cancer
GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the product for use in combination with chemotherapy as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are
EC expands approval for Jemperli
The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy,
EC approves GSK’s Jemperli-chemo combo for endometrial cancer
The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer in adults.
EU approves endometrial, lung cancer drugs from GSK and J&J
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first-line treatment for locally advanced and metastatic NSCLC with exon 19 deletions or exon 21 L858R substitutions.
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0
GSK: European Commission Expands Jemperli Plus Chemotherapy Approval - Quick Facts
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line
European Commission expands Jemperli (dostarlimab)…
GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic
GSK announces expanded EU approval in endometrial cancer for Jemperli combo
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
Daily3d
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...